Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. They are pioneers in translating the science of RNAi into a new class of innovative medicines, targeting a wide range of diseases, including genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. Alnylam aims to address diseases with high unmet medical need, transforming the lives of patients worldwide.
The Cambridge headquarters serves as the central hub for Alnylam's global operations, including research and development, corporate strategy, executive leadership, and administrative functions.
The headquarters features state-of-the-art laboratory facilities, modern office spaces designed for collaboration, and is situated within Kendall Square, known for its dense concentration of biotech and pharmaceutical companies and academic institutions like MIT.
Alnylam fosters an innovative, science-driven, and patient-focused work culture. Collaboration, scientific rigor, and a commitment to making a difference in patients' lives are core tenets of the work environment.
Its location in Kendall Square provides Alnylam with unparalleled access to talent, research collaborations, and a vibrant ecosystem of innovation, crucial for its leadership in RNAi therapeutics.
Alnylam Pharmaceuticals maintains a significant global presence to support its mission of bringing RNAi therapeutics to patients worldwide. This includes global clinical trial operations spanning numerous countries, regional headquarters and offices in North America, Europe (UK, Switzerland), and Asia-Pacific (Japan), dedicated teams for manufacturing and supply chain logistics, worldwide regulatory affairs management, and commercial teams to launch and support their products in approved markets.
675 West Kendall Street
Cambridge
MA
USA
Address: Alnylam UK, Ltd., Braywick Gate, Braywick Road, Maidenhead, Berkshire, SL6 1DA, UK
To manage and expand Alnylam's presence and product portfolio within the EMEA markets, ensuring patient access to their innovative RNAi therapies.
Address: Alnylam Switzerland GmbH, Grafenauweg 10, 6300 Zug, Switzerland
To spearhead commercialization and market access efforts in Switzerland and other international territories outside the US and EMEA, contributing to Alnylam's global reach.
Address: Alnylam Japan KK, Marunouchi Park Building, 2-6-1 Marunouchi, Chiyoda-ku, Tokyo 100-6913, Japan
To establish and grow Alnylam's footprint in the Japanese pharmaceutical market, addressing unmet medical needs with RNAi therapeutics.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Alnylam Pharmaceuticals' leadership includes:
Alnylam Pharmaceuticals has been backed by several prominent investors over the years, including:
Alnylam has seen key leadership appointments and transitions in the past year, notably strengthening its human resources function and experiencing a change in the Chief Medical Officer role.
Discover the tools Alnylam Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Alnylam Pharmaceuticals commonly uses the first initial followed by the last name for their email addresses. For example, Jane Doe would likely be jdoe@alnylam.com.
[first_initial][last]@alnylam.com
Format
jdoe@alnylam.com
Example
90%
Success rate
Alnylam Pharmaceuticals • May 2, 2024
Alnylam announced its Q1 2024 financial results, highlighting product revenue growth and advancements in its clinical pipeline, including progress with zilebesiran for hypertension....more
Alnylam Pharmaceuticals • March 26, 2024
Alnylam announced the full results from its KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic for hypertension, were published in NEJM, showing positive efficacy and safety....more
Alnylam Pharmaceuticals • March 4, 2024
Alnylam shared positive topline results from the KARDIA-2 Phase 2 study, demonstrating zilebesiran's potential in treating uncontrolled hypertension when added to standard antihypertensive treatments....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Alnylam Pharmaceuticals, are just a search away.